Comparison · NCT02014584-87db7d13
Dutasteride 0.5 mg vs Placebo: Incidence of Premature Discontinuations in the Double-blind Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dutasteride 0.5 mg vs Placebo: Incidence of Premature Discontinuations in the Double-blind Treatment Period. Trial comparisons, record NCT02014584-87db7d13. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02014584-87db7d13
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.103 | 0.0483 | 0.208 | wilson | |
| Risk in group 2 | 0.0339 | 0.00935 | 0.115 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0695 | -0.0289 | 0.177 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.05 | 0.642 | 14.5 | log | |
| Odds ratio, group 1 over group 2 | 3.29 | 0.635 | 17 | log | |
| Number needed to treat, for one more participant with the outcome on Dutasteride 0.5 mg than on Placebo | 14.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dutasteride 0.5 mg | Participants received dutasteride 0.5 mg administered orally once daily for 24 weeks. | 6 | 58 | OG001 |
| Group 2 | Placebo | Participants received placebo administered orally once daily for 24 weeks. | 2 | 59 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of Premature Discontinuations in the Double-blind Treatment Period
- Description
Participants were referred as premature discontinuations if they do not complete the double-blind period. The reasons for premature withdrawal were protocol deviation, lost to follow-up and withdrawal of consent by participants.
- Time frame
- Week 24
- Population
- ITT population
Source ClinicalTrials.gov
Trial
- Title
- Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
- NCT number
- NCT02014584
- Phases
- PHASE3
- Conditions
- Alopecia
- Interventions
- Dutasteride, Placebo
- Lead sponsor
- Stiefel, a GSK Company
- Results first posted
- 2017-03-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02014584?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02014584-87db7d13